Eye movements in genetic parkinsonisms affecting the α-synuclein, PARK9, and manganese network

[1]  M. Aschner,et al.  Untangling the Manganese-α-Synuclein Web , 2016, Front. Neurosci..

[2]  B. Gaymard,et al.  Eye Movements in Ephedrone-Induced Parkinsonism , 2014, PloS one.

[3]  B. Oostra,et al.  Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. , 2012, American journal of human genetics.

[4]  Masaya Segawa,et al.  Initiation and inhibitory control of saccades with the progression of Parkinson's disease – Changes in three major drives converging on the superior colliculus , 2011, Neuropsychologia.

[5]  A. Sprenger,et al.  Eye movement disorders in ATP13A2 mutation carriers (PARK9) , 2010, Movement disorders : official journal of the Movement Disorder Society.

[6]  S. Pappatà,et al.  Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability , 2010, neurogenetics.

[7]  S. Lindquist,et al.  α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.

[8]  Jan Gründemann,et al.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.

[9]  A. Lees,et al.  Kufor Rakeb Disease: Autosomal recessive, levodopa‐responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[10]  Douglas C. Miller,et al.  A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.